Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081700 · ClinicalTrials.gov registry record
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis
A clinical trial, sponsored by Providence Health & Services.
- Completed
- Registry status
- 14
- Enrollment target
NCT05081700 is a clinical trial that has completed, run by Providence Health & Services. The registered enrollment target is 14 participants.
The verdict
NCT05081700 has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This pilot study will establish a proof of concept for using a systems biology approach to characterize the dynamics of MS disease processes. The primary objective of the study is to identify multi-omic (genetic, proteomic, biochemical and/or microbial) factors that correlate with clinical and subclinical MS disease activity. Identification of such biomarkers could have an immediate clinical utility in identification of MS patients prone to more aggressive disease earlier in their disease course, thus affording the opportunity to better individualize therapy. In addition, insights from better understanding of the complex interplay of various systems biology factors should improve our understanding of MS in general. The study will recruit 14 patients with relapsing MS who are initiating treatment with ocrelizumab, and follow them for 30 months.
Interventions
- DRUG All patients in the study will be treated with ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2023-11-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05081700
The ClinicalTrials.gov registry entry for NCT05081700 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All patients in the study will be treated with ocrelizumab is the first listed.
NCT05081700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05081700 about?
NCT05081700 is a clinical study titled "A Systems Approach to Understanding Disease Processes in Multiple Sclerosis". This pilot study will establish a proof of concept for using a systems biology approach to characterize the dynamics of MS disease processes. The primary objective of the study is to identify multi-omic (genetic, proteomic, biochemical and/or microbial) factors that correlate with clinical and subcl...
What is the current status of trial NCT05081700?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2020-05-11. Estimated completion is 2023-11-03.
What interventions are being tested in trial NCT05081700?
The interventions under investigation include: All patients in the study will be treated with ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT05081700?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.